Anti-VEGF Market Growth Accelerates with Rising Eye Disease Prevalence, Says Persistence Market Research

The global Anti-Vascular Endothelial Growth Factor (Anti-VEGF) market has been gaining significant traction due to the rising prevalence of cancer and advancements in biologic drug formulations. As per the latest report by Persistence Market Research, the market was valued at US$ 25.2 Billion in 2025 and is projected to reach US$ 33.1 Billion by 2032, expanding at a CAGR of 4.0% during the forecast period.

Anti-VEGF therapy, which works by inhibiting the formation of new blood vessels in tumors and ocular disorders, has become a cornerstone in cancer and retinal disease treatment. Biologics, with a 73.3% market share in 2024, are leading the product type segment due to their high efficacy and extended half-life. Geographically, North America, particularly the United States, remains the dominant region, bolstered by a robust healthcare infrastructure, favorable reimbursement policies, and a high incidence of cancer.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/33422

Key Highlights from the Report

• The Anti-VEGF market is forecasted to grow from US$ 25.2 Billion in 2025 to US$ 33.1 Billion by 2032.
• Biologics led the market with a 73.3% share in 2024 due to their clinical effectiveness and patent exclusivity.
• Oncology applications dominated with a 95.5% market share in 2024.
• VEGF-A inhibitors held a 49.1% share owing to their broad efficacy across multiple cancer types.
• The United States captured 95.2% of the North American market in 2024.
• China is rapidly emerging, holding 48.7% of East Asia's market due to government healthcare initiatives.

Market Segmentation

The Anti-VEGF market is segmented by product type, disease indication, and end-user. In terms of product type, biologics remain the top-selling category. Their specificity, superior bioavailability, and longer half-life make them highly suitable for chronic conditions like cancer and age-related macular degeneration. Biosimilars are gradually gaining momentum, especially in cost-sensitive markets, due to their affordability and recent regulatory approvals.

By disease indication, oncology is the predominant segment, accounting for 95.5% of the market share in 2024. This is largely attributed to the increasing burden of cancers like colorectal, kidney, and non-small cell lung cancer. The use of VEGF inhibitors in treating ocular conditions such as age-related macular degeneration (AMD) and diabetic macular edema is also expanding, but oncology remains the primary driver of global sales.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/anti-vegf-market.asp

Regional Insights

North America, led by the United States, is the largest regional market for anti-VEGF drugs. This can be attributed to high cancer prevalence, a technologically advanced healthcare system, and the early adoption of biologics. The presence of key pharmaceutical players and favorable reimbursement systems further fuel growth in the region.

In contrast, Asia Pacific is emerging as a fast-growing market due to rising healthcare investments and government support. China, in particular, has shown notable progress, driven by healthcare reforms, reimbursement inclusions, and an increasing elderly population prone to cancer and retinal diseases.

Market Drivers

One of the core drivers of the anti-VEGF market is the rising global cancer burden. As cancer continues to be a leading cause of mortality worldwide, demand for targeted therapies like VEGF inhibitors has grown exponentially. Additionally, regulatory approvals, such as the FDA's greenlight for biosimilars and combination therapies, have expanded treatment options and improved patient access.

Innovations in ocular drug delivery systems, including liposome-based and dendrimer-conjugated formulations, are also revolutionizing VEGF inhibitor applications beyond oncology. These technologies enable prolonged drug release, increasing efficacy in retinal treatments while reducing dosing frequency.

Market Restraints

Despite its strong growth potential, the anti-VEGF market is not without challenges. Adverse effects associated with VEGF inhibitors-such as bleeding complications, hypertension, and thromboembolic events-pose significant clinical concerns. These side effects can limit widespread use and prompt clinicians to seek alternative therapies.

Another restraint is the high cost of biologics, particularly in low- and middle-income countries. For instance, the average sales price of aflibercept and ranibizumab is approximately US$ 1877 and US$ 1717 per dose, respectively. This has led to increased use of off-label, lower-cost alternatives like bevacizumab, thereby affecting revenues for branded drugs.

Market Opportunities

Significant opportunities lie in the expansion of biosimilars and the rising demand in emerging economies. With increasing regulatory clarity and successful trials, biosimilars like bevacizumab-maly (ALYMSYS) are entering the market, offering cost-effective options and increasing accessibility.

Additionally, increasing government investments in healthcare infrastructure across regions such as Asia-Pacific, Latin America, and the Middle East are opening new avenues for market expansion. Strategic collaborations and clinical trials focusing on new indications beyond oncology, such as rheumatoid arthritis and chronic kidney disease, could further fuel future growth.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/33422

Reasons to Buy the Report

• Comprehensive analysis of market trends, drivers, restraints, and future opportunities.
• In-depth segmentation insights by product type, indication, and geography.
• Profiles and strategic developments of top industry players.
• Forecast data till 2032, aiding long-term business planning.
• Access to detailed competitive landscape and regional market performance.

Frequently Asked Questions (FAQs)

• How big is the Anti-VEGF Market in 2025?
• What is the projected growth rate of the Anti-VEGF market through 2032?
• Who are the key players in the global Anti-VEGF market?
• What is the market forecast for Anti-VEGF drugs in 2032?
• Which region is estimated to dominate the Anti-VEGF industry during the forecast period?

Company Insights

Key Players Operating in the Anti-VEGF Market:

• Pfizer Inc.
• Bayer AG
• Novartis AG
• Sanofi SA
• Exelixis Inc.
• Eisai Co. Ltd.
• Amgen Inc.
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Amneal Pharmaceuticals Inc.
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Sino Biopharma

Recent Developments:

• In May 2023, Eli Lilly and Company's CYRAMZA® received FDA approval for treating advanced non-small cell lung cancer (NSCLC).
• In April 2023, Amneal Pharmaceuticals obtained FDA approval for bevacizumab-maly (ALYMSYS), expanding the biosimilar portfolio in the U.S.

Conclusion

The Anti-VEGF market is poised for steady growth through 2032, driven by a rising global cancer burden, advancements in biologics, and expanding applications in ophthalmology. North America remains at the forefront, while Asia-Pacific offers lucrative opportunities due to evolving healthcare infrastructure and growing patient populations.

Despite high costs and potential side effects, the demand for targeted and efficient treatments ensures a strong future for anti-VEGF therapies. With continued regulatory approvals, biosimilar launches, and technological innovations, market stakeholders are well-positioned to tap into both developed and emerging economies. Companies that can innovate and adapt to regional healthcare dynamics will lead the next wave of growth in the anti-VEGF market.

Read More Related Reports:

Dental Implant Abutment Systems Market https://www.persistencemarketresearch.com/market-research/dental-implant-abutment-systems-market.asp
Medical Patches And Sensors Market https://www.persistencemarketresearch.com/market-research/medical-patches-and-sensors-market.asp
Endoscopic Mucosal Resection Market https://www.persistencemarketresearch.com/market-research/endoscopic-mucosal-resection-market.asp
Extracorporeal Membrane Oxygenation Device Market https://www.persistencemarketresearch.com/market-research/extracorporeal-membrane-oxygenation-device-market.asp
Laser Diffraction Equipment Market https://www.persistencemarketresearch.com/market-research/laser-diffraction-equipment-market.asp

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.